论文部分内容阅读
目的评价特雷唑来对不同耐药类型的结核分枝杆菌临床分离株的体外抑菌作用,为临床应用提供实验依据。方法采用微孔板观察法,测定特雷唑来对标准株H37Rv及临床分离的敏感、单耐药、多耐药、耐多药以及广泛耐药各20株(共100株)的MIC,再测定特雷唑来与7种常用抗结核药物联合使用时,对H37Rv和10株MTB临床分离株(敏感、单耐药、多耐药、耐多药以及广泛耐药各2株)的MIC,通过计算分级抑菌浓度指数(FICI),观察特雷唑来对结核分枝杆菌的体外抑菌作用以及与其他抗结核药物联合使用时是否有协同作用。结果 94.0%(94/100)的结核分枝杆菌临床分离株可被≤0.5mg/L的特雷唑来抑制生长,特雷唑来对敏感株、MDR菌株(耐多药和广泛耐药)及非MDR耐药菌株(单耐药和多耐药)的MIC差异无统计学意义(χ~2=0.578,P>0.05)。特雷唑来与7种抗结核药物在体外联合使用时对结核标准菌株H37Rv和临床分离株均未表现出相关性。结论特雷唑来对结核分枝杆菌,尤其是耐多药和广泛耐药菌株,均有很好的体外抑菌作用,且与细菌对其他抗结核药物是否耐药无关。
Objective To evaluate the bacteriostasis of telbivudine against clinical isolates of Mycobacterium tuberculosis of different drug resistance types in vitro and provide experimental basis for its clinical application. Methods The microtiter plate wells were used to measure the MIC of standard strain H37Rv and sensitive, single-drug resistant, multi-drug resistant, multidrug-resistant and multi-drug resistant strains of 20 strains (100 strains in total) When telbivudine was used in combination with 7 commonly used anti-TB drugs, the MICs of H37Rv and 10 strains of MTB clinical isolates (2 sensitive, 2 resistant, multidrug resistant, multidrug resistant and 2 multidrug resistant) By calculating the fractional inhibitory concentration index (FICI), observe the bacteriostatic effect of telbuterol on M. tuberculosis in vitro and whether there is a synergistic effect when used in combination with other anti-TB drugs. Results 94.0% (94/100) of Mycobacterium tuberculosis clinical isolates could be inhibited by ≤0.5 mg / L telbuterol, and telbivudine was effective against sensitive strains, MDR strains (MDR and extensively drug resistant) There was no significant difference in the MICs between the MDR-resistant and multi-drug resistant strains (χ ~ 2 = 0.578, P> 0.05). No combination of tuberculosis standard strain H37Rv with clinical isolates was found when terezolan was administered in combination with seven anti-TB drugs in vitro. Conclusion Triptolide has good antimicrobial activity in vitro against Mycobacterium tuberculosis, especially multidrug-resistant and drug-resistant strains, and has nothing to do with the bacterial resistance to other anti-tuberculosis drugs.